Telix Pharmaceuticals Ltd has released a press release.
First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Completes Acquisition of Lightpoint Medical
- ProstACT SELECT Study of TLX591 Positive Interim Readout
- Q3 2023 Business Update to Accompany Quarterly Results
- Activities Report and Appendix 4C - September 2023 Quarter
- 1H 2023 Results Release
Later from Telix Pharmaceuticals
- Telix Announces Proposed Acquisition of QSAM Biosciences
- Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
- Telix Plans U.S. Registered Public Offering and Listing
- JP Morgan Healthcare Conference and Trading Update
- JP Morgan Healthcare Conference Presentation
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals